
|Videos|November 14, 2020
AAO 2020: Considerations when using anti-VEGF for treating AMD
Author(s)OTE Staff Reports
Prof. Giovanni Staurenghi, chairman of the University Eye Clinic, Department of Biomedical and Clinical Sciences at the University of Milan’s Luigi Sacco Hospital, Italy, discusses his presentation from this year's AAO, including findings from the HARBOR study of macular atrophy in AMD patients treated with ranibizumab.
Advertisement
Prof. Giovanni Staurenghi, chairman of the University Eye Clinic, Department of Biomedical and Clinical Sciences at the University of Milan’s Luigi Sacco Hospital, Italy, discusses his presentation from this year's AAO, including findings from the HARBOR study of macular atrophy in AMD patients treated with ranibizumab.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA approves phentolamine ophthalmic solution 0.75% (Ryzumvi) for presbyopia
2
Alvotech files first known aflibercept 8 mg biosimilar with EMA
3
Duravyu misses noninferiority end point in phase 3 LUCIA wet AMD trial
4
FDA approves subcutaneous Enspryng for TED
5

















